ERGi-USU-6 (mesylate)
ERGi-USU-6 mesylate (Compound 7b) is an inhibitor of ERG and RIOK2 (IC50 values: 0.17 and 0.13 μM in VCaP cells, respectively) . ERGi-USU-6 mesylate exhibits anticancer activity against ERG-positive prostate cancer[1].
Product Specifications
CAS Number
2756327-67-8
UNSPSC
12352005
Target
Ser/Thr Kinase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ergi-usu-6-mesylate.html
Purity
95.0
Solubility
DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 160°C)
Smiles
OC1=CC(N(C)C)=CC=C1/N=N/C2=NC=CC=C2.CS(O)(=O)=O
Molecular Formula
C14H18N4O4S
Molecular Weight
338.38
References & Citations
[1]Eldhose B, et al. New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. ACS Med Chem Lett. 2021 Oct 19;12 (11) :1703-1709.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
